Alnylam Joins Max Planck in Suit Against Whitehead, UMass, MIT Over Tuschl IP Portfolio

The lawsuit alleges that the defendants have sought to include in their patent applications inventions that belong solely to Max Planck and licensed exclusively to Alnylam. While licenses to the IP have been a big moneymaker for Alnylam, some companies have begun looking to alternative RNAi technologies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.